Trial Profile
The irbesartan in patients with type 2 diabetes and microalbuminuria (IRMA 2)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 29 Sep 2020
Price :
$35
*
At a glance
- Drugs Irbesartan (Primary)
- Indications Diabetic nephropathies; Hypertension; Hypertension in diabetes; Proteinuria
- Focus Therapeutic Use
- Acronyms IRMA-2
- 22 Sep 2020 Results investigating individuals with type 2 diabetes, whether irbesartan lowered plasma levels of the dicarbonyls methylglyoxal, glyoxal, 3-deoxyglucosone and their derived advanced glycation end products (AGEs), and increased D-lactate, reflecting greater methylglyoxal flux published in the Diabetic Medicine
- 31 Mar 2011 Results from a sub-study investigating the effects of treatment on nucleic acid oxidation published in the Diabetes Care.
- 24 Sep 2010 Results from a sub-study investigating the effects of treatment on renal function presented at the 46th Annual Meeting of the European Association for the Study of Diabetes